Showing results (71-80 of 87) with videos related to
Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemiaR Dorr, C Karanes, C Spier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1988
Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcomeA F List, J P Greer, J C Cousar, et al.The Journal of Pharmacology and Experimental Therapeutics|August 11, 2004
Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarraysM Nouzova, N Holtan, M M Oshiro, et al.Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.Neuroscience|September 29, 2011
Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressorD M Kerr, N N Burke, G K Ford, et al.Bone Marrow Transplantation|February 16, 2000
A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study GroupA F List, R Maziarz, P Stiff, et al.Blood|March 15, 1996
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemiaA F List, C S Spier, T M Grogan, et al.Ecancermedicalscience|January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.Blood|November 24, 2001
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group studyA F List, K J Kopecky, C L Willman, et al.Leukemia|July 16, 2011
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemiaJ E Lancet, F Ravandi, R M Ricklis, et al.Pageof 9